Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

419 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Systemic Therapy for Melanoma: ASCO Guideline Update.
Seth R, Agarwala SS, Messersmith H, Alluri KC, Ascierto PA, Atkins MB, Bollin K, Chacon M, Davis N, Faries MB, Funchain P, Gold JS, Guild S, Gyorki DE, Kaur V, Khushalani NI, Kirkwood JM, McQuade JL, Meyers MO, Provenzano A, Robert C, Santinami M, Sehdev A, Sondak VK, Spurrier G, Swami U, Truong TG, Tsai KK, van Akkooi A, Weber J. Seth R, et al. Among authors: atkins mb. J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14. J Clin Oncol. 2023. PMID: 37579248
Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH. Falkson CI, et al. Among authors: atkins mb. J Clin Oncol. 1998 May;16(5):1743-51. doi: 10.1200/JCO.1998.16.5.1743. J Clin Oncol. 1998. PMID: 9586887 Clinical Trial.
Patient preferences for adjuvant interferon alfa-2b treatment.
Kilbridge KL, Weeks JC, Sober AJ, Haluska FG, Slingluff CL, Atkins MB, Sock DE, Kirkwood JM, Nease RF. Kilbridge KL, et al. Among authors: atkins mb. J Clin Oncol. 2001 Feb 1;19(3):812-23. doi: 10.1200/JCO.2001.19.3.812. J Clin Oncol. 2001. PMID: 11157035
High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.
Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB. Kirkwood JM, et al. Among authors: atkins mb. J Clin Oncol. 2001 Mar 1;19(5):1430-6. doi: 10.1200/JCO.2001.19.5.1430. J Clin Oncol. 2001. PMID: 11230488 Clinical Trial.
An evidence-based staging system for cutaneous melanoma.
Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Balch CM, et al. Among authors: atkins mb. CA Cancer J Clin. 2004 May-Jun;54(3):131-49; quiz 182-4. doi: 10.3322/canjclin.54.3.131. CA Cancer J Clin. 2004. PMID: 15195788 Free article. Review.
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB. McDermott DF, et al. Among authors: atkins mb. J Clin Oncol. 2005 Jan 1;23(1):133-41. doi: 10.1200/JCO.2005.03.206. J Clin Oncol. 2005. PMID: 15625368 Clinical Trial.
419 results